What is Roth Capital’s Forecast for CELZ Q1 Earnings?

Posted by MarketBeat News on Nov 16th, 2024

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) – Stock analysts at Roth Capital issued their Q1 2025 earnings estimates for shares of Creative Medical Technology in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff expects that the company will earn ($0.64) per share for the quarter. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.29) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.54) EPS and Q4 2025 earnings at ($0.54) EPS.

Creative Medical Technology Stock Up 1.5 %

CELZ opened at $2.70 on Friday. The business’s fifty day simple moving average is $3.47 and its 200 day simple moving average is $3.70. Creative Medical Technology has a 52 week low of $2.52 and a 52 week high of $10.28. The stock has a market cap of $4.73 million, a PE ratio of -0.71 and a beta of 2.01.

Hedge Funds Weigh In On Creative Medical Technology

Want More Great Investing Ideas?

An institutional investor recently bought a new position in Creative Medical Technology stock. Virtu Financial LLC purchased a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned 1.21% of Creative Medical Technology at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.